SIBIONICS
Innovating for You: Revolutionizing Diabetes Care with Every Step.
Since our founding in 2015, SIBIONICS has been at the forefront of transforming diabetes management. Born from a commitment to innovation and a profound understanding of the everyday challenges faced by those with diabetes, we've consistently aimed to redefine the landscape of Continuous Glucose Monitoring (CGM) systems. By merging cutting-edge technology with designs centered around the user, we deliver solutions that not only meet needs but exceed expectations.
Today, with over 1,000,000 users across the globe, SIBIONICS stands as a beacon of reliability and innovation in diabetes care. Our global presence is a testament to the effectiveness of our CGM solutions and our dedication to making a significant, positive impact worldwide.
Looking ahead, SIBIONICS is committed to continuing our legacy of innovation. We're not just keeping pace; we're setting the pace—constantly pushing the boundaries of what's possible in CGM technology and striving for excellence with each new product we introduce.
創新底層技術，服務公共衛生
我們關注最廣泛人口的健康管理需求，也關心罕見病患的疾病診斷和治療方案。我們整合了優秀的科學家團隊，不斷將前沿科研成果轉化為醫療產品，服務大眾健康。
科技洞察未知激發生命潛能
根據患者需求，引入生物化學、晶片設計、人工智慧、自動化等技術，洞察健康數據未知領域，幫助人們做出改變，邁向更好的生活質量
證書
我們致力於協助客戶提升產品品質並應對挑戰。
里程碑和產品陣容
2023
The GS1 CGM system received the CE mark for entering the European market.
2021
The continuous glucose monitoring system (CGM) was submitted to National Medical Products Administration for registration and was approved. The practicing license of Yinchuan Sibionics Internet Hospital was approved.
2020
AI-DR was approved as the first Class III medical device for AI-assisted fundus disease diagnosis software in China. Sibionics was certified as National High-tech Enterprise.
2019
Fundus camera obtained the registration certificate for Class II medical device. R&D of capsule endoscopy project was started.
2016
R&D of continuous glucose monitoring system (CGM) was started. R&D of diabetic retinopathy AI-assisted diagnosis software (AI-DR) was started.
2015
Sibionics was established, and American R&D Center was established. R&D of artificial retina project was started.
